Henry Schein Inc. (HSIC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HSIC scores 60 out of 100, earning a C- grade and the verdict "Roarable Hold — Cautious Neutral." The five pillars break down as follows. Fundamental Cash Engine scores 9 of 20 (ROIC 11.2%; FCF yield 1.23%), the weakest pillar and the one most directly tied to whether the business is generating cash relative to its price. Whale 13F Flow scores 13 of 20 (institutional accumulation and options positioning), indicating moderate institutional interest. Insider Conviction scores 12 of 20 (SEC Form 4 and Congressional PTR cluster flow), a middling reading. Macro Regime Fit scores 12 of 20 (Beta 0.89; sector sensitivity), suggesting a lower-than-market beta profile. Forensic Balance Sheet scores 14 of 20 (Altman Z 2.81; Piotroski F 7/9; Debt/Equity 0.83), the strongest pillar.

For a prospective investor, the upside case rests mainly on balance-sheet resilience and a below-market beta, which may cushion drawdowns. The valuation tradeoff is that the stock trades at a trailing P/E of 23 and an EV/EBITDA of 9.5 against a thin 1.23% FCF yield, so the market is paying for earnings the cash flow has not yet fully confirmed. The 60 score and "Hold" verdict reflect that mix: financial strength without a compelling cash-yield entry point.

Per the SEC financials, revenue rose from $12339.0M in FY 2023 to $13184.0M in FY 2025, while net income moved from $436.0M to $419.0M over the same span. Market data reports a gross margin of 31.1%, an operating margin of 5%, and a net margin of 3.2%, with ROIC of 11.2%. The Roarable RQD rating cites an Altman Z-Score of 2.81 and a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.83. Free cash flow fell from $277.7M in FY 2024 to $118.7M in FY 2025, and debt rose from $2421.4M to $2889.4M over the same period.

Six headlines appear in the news feed, all tagged to HSIC:

• Yahoo Finance coverage asking whether value investors should buy the stock (YELLOW, Market Wire).
• TradingView coverage previewing a Q3 earnings report (YELLOW, Market Wire).
• Yahoo Finance coverage of renewed market attention (YELLOW, Market Wire).
• The Globe and Mail coverage comparing Q2 earnings with other dental equipment and technology stocks (YELLOW, Market Wire).
• TradingView coverage of a 12-month price target cut to $97.27, implying 16% upside (RED, Risk Watch).
• Simply Wall Street coverage of why the stock is drawing attention (YELLOW, Market Wire).

The single RED item is the price-target cut, flagged as a risk watch item. The Q3 earnings preview is the nearest scheduled catalyst. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.

• What is the company's product mix, customer base, and revenue model? The source data gives only the sector and industry classification.
• Why is EPS reported as N/A for all three fiscal years, and what is cash on hand? Both are missing from the financials table.
• What drove the decline in FCF from $277.7M to $118.7M, and does the debt increase relate to that change?
• Which analyst firms issued the price-target cut, and what is the consensus rating?
• What is the Q3 earnings date and consensus expectation referenced in the preview headline?